Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge

Table 1

Baseline Characteristics according to time in therapeutic range.

	Total cohort (n=212)	TTR <70 (n=128, 60.4)	TTR ≥70 (n=84, 39.6)	p-value
Age, years	74 ± 9.0	74 ± 8.8	73 ± 9.2	0.286
Male gender, n ()	105 (50.0)	63 (49.2)	42 (50.0)	0.911
Body mass index, kg/m^2	30.9 ± 5.2	30.2 ± 4.8	32 ± 5.5	0.013
Current smoking, n ()	22 (10.4)	14 (10.9)	8 (9.5)	0.741
Dyslipidaemia, n ()	100 (47.2)	58 (45.3)	42 (50.0)	0.504
Hypertension, n ()	158 (75.0)	91 (71.1)	67 (79.8)	0.157
Type 2 diabetes mellitus, n ()	63 (29.7)	34 (26.6)	29 (34.5)	0.215
Previous heart failure, n ()	40 (18.9)	29 (22.7)	11 (13.1)	0.082
Previous stroke, n ()	20 (9.4)	14 (10.9)	6 (7.1)	0.355
Previous ischemic heart disease, n ()	47 (22.2)	29 (22.7)	18 (21.4)	0.833
Previous peripheral arterial disease, n ()	16 (7.5)	11 (8.6)	5 (6.0)	0.476
Previous pulmonary disease, n ()	51 (24.1)	33 (25.8)	18 (21.4)	0.468
Previous renal disease, n ()	27 (12.7)	18 (14.1)	9 (10.7)	0.474
Previous hepatic disease, n ()	1 (0.5)	1 (0.8)	0	1
Previous neoplasm, n ()	22 (10.4)	11(8.6)	11 (13.1)	0.293
Charlson score	1.3 ± 1.5	1.4 ± 1.5	1.3 ± 1.4	0.505
Alcohol intake, grams per day	4.2 ± 7.1	4.2 ± 7.5	4.2 ± 6.5	0.951
Regular vitamin K intake	138 (65.1)	76 (59.4)	62 (73.8)	0.031
Persistent or permanent atrial fibrillation, n ()	128 (60.4)	84 (65.6)	44 (52.4)	0.054
SAMe-TT2R2 score	1.3 ± 1.0	1.2 ±0.9	1.3 ± 1.1	0.522
Age < 60 years, n ()	15 (7.1)	7 (5.5)	8 (9.5)	0.260
Medical history, n ()	64 (30.2)	38 (29.7)	26 (31.0)	0.844
Treatment (interacting medications), n ()	58 (27.4)	35 (27.3)	23 (27.4)	0.995
Non-Caucasian race, n ()	1 (0.5)	1 (0.8)	0	1
Number of active medications	7.3 ± 3.0	7.6 ± 3.1	6.9 ± 2.9	0.088
≥ 7 active medications ()	112 (52.8)	72 (56.3)	40 (47.6)	0.218
Estimated glomerular filtration rate, ml/min/1.73m^2	73.6 ± 26.4	72.6 ± 24.6	75.2 ±29.1	0.487

TTR, time in therapeutic range; CI, confidence interval. Medical history: hypertension, diabetes mellitus, ischemic heart disease, peripheral arterial disease, heart failure, previous stroke, pulmonary disease, and liver or renal disease. Number of active medications: number of tablets taken per day apart from VKA. 7 corresponds to the median value of number of active medications.